Insight Molecular Diagnostics Inc (IMDX)

$7.40 -0.45 (-5.73%)
Market Cap 225.01M
Revenue (ttm) 1.88M
Net Income (ttm) -60.66M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -3,226.60%
Debt to Equity Ratio 0.00
Volume 209,300
Avg Vol 74,054
Day's Range N/A - N/A
Shares Out 28.66M
Stochastic %K 59%
Beta 1.34
Analysts Sell
Price Target $7.00

Company Profile

Insight Molecular Diagnostics Inc. operates as a precision diagnostics company in the United States and internationally. The company develops and commercializes laboratory developed tests, kitted research use only tests, and kitted clinical tests. It is developing DetermaCNI, a blood-based monitoring tool that detects progression early after one cycle cancer treatment; and DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies. The compa...

Industry: Diagnostics & Research
Sector: Healthcare
Phone: 949 409 7600
Website: imdxinc.com
Address:
2 International Plaza Dr., Suite 510, Nashville, United States
DefenestrationAtPrague
DefenestrationAtPrague Nov. 13 at 4:31 AM
$IMDX I already own more than renaissance, buying 5k more shares tomorrow. If only they had options back… Price Target is a reflection of M&A
1 · Reply
afc2881
afc2881 Nov. 12 at 11:17 PM
$IMDX John here since 2018!
1 · Reply
crypto_vibe67
crypto_vibe67 Nov. 12 at 8:49 PM
$IMDX NXXT grind then jump classic markup rhythm 🧗
0 · Reply
cache1b
cache1b Nov. 12 at 8:43 PM
$IMDX still in
0 · Reply
ocxfan
ocxfan Nov. 12 at 8:27 PM
$IMDX
1 · Reply
Cynovarx_917
Cynovarx_917 Nov. 12 at 8:25 PM
$IMDX
0 · Reply
PulseFocus2587
PulseFocus2587 Nov. 12 at 8:03 PM
$IMDX NXXT bidders fearless, offers thin, door open
0 · Reply
jackedmund99
jackedmund99 Nov. 12 at 7:58 PM
$IMDX very interesting that institutions own close to 51% of the stock insiders own close to 42% of the stock institutional fund ownership owns 2% of the stock and everyone else owns the rest amazing. The stock is hasn’t even been discovered.
1 · Reply
jackedmund99
jackedmund99 Nov. 12 at 7:49 PM
$IMDX need him and Company yesterday raised the target on the stock to nine dollars from 4 1/2 but it’s next week when I have to raise it to the mid teens market cap for this company should be easily could be $500 million right now it’s not overpriced
1 · Reply
jackedmund99
jackedmund99 Nov. 12 at 7:20 PM
$IMDX technology is being validated market cap still at $200 million is peanuts stock can literally be worth twice as much when the first dollar is cashed and that’s where it should be. This is probably a half $1 billion company before they start to sell product technology works going after huge market. It’s just the beginningthe fact that the stock is not getting trashed and it’s in tight hands. The best is yet to come fuck the shorts
1 · Reply
Latest News on IMDX
Insight Molecular Diagnostics Inc. (IMDX) Q3 2025 Earnings Call Transcript

Nov 11, 2025, 7:31 AM EST - 3 days ago

Insight Molecular Diagnostics Inc. (IMDX) Q3 2025 Earnings Call Transcript

IMDX Reports Q3 2025 Results and Progress Toward 2026 Commercial Launch

Nov 10, 2025, 4:05 PM EST - 4 days ago

IMDX Reports Q3 2025 Results and Progress Toward 2026 Commercial Launch

iMDx to Release Third Quarter 2025 Results on November 10 and Attend Stephens Annual Investment Conference the Following Week

Nov 3, 2025, 4:05 PM EST - 11 days ago

iMDx to Release Third Quarter 2025 Results on November 10 and Attend Stephens Annual Investment Conference the Following Week

iMDx Welcomes New VP Marketing to Prepare for Commercial Transplant Assay Launch

Oct 13, 2025, 4:05 PM EDT - 4 weeks ago

iMDx Welcomes New VP Marketing to Prepare for Commercial Transplant Assay Launch

iMDx Reports Kidney Transplant Patient Achieved ‘Immune Reset' with Novel Therapy and GraftAssure Monitoring

Oct 6, 2025, 7:15 AM EDT - 5 weeks ago

iMDx Reports Kidney Transplant Patient Achieved ‘Immune Reset' with Novel Therapy and GraftAssure Monitoring

Insight Molecular Diagnostics to Showcase Leadership in Kidney Transplant Management at Conferences in Singapore and Orlando

Sep 24, 2025, 7:05 AM EDT - 7 weeks ago

Insight Molecular Diagnostics to Showcase Leadership in Kidney Transplant Management at Conferences in Singapore and Orlando

Insight Molecular Diagnostics Announces Positive Strategic Update and Novel Registry Database

Sep 8, 2025, 7:15 AM EDT - 2 months ago

Insight Molecular Diagnostics Announces Positive Strategic Update and Novel Registry Database

IMDX Enrolls First Patient in GraftAssureDx Clinical Trial and Welcomes New Hospital Participants

Sep 8, 2025, 7:00 AM EDT - 2 months ago

IMDX Enrolls First Patient in GraftAssureDx Clinical Trial and Welcomes New Hospital Participants

iMDx to Participate in NYC Investment Conferences September 8 - 11

Aug 26, 2025, 4:05 PM EDT - 2 months ago

iMDx to Participate in NYC Investment Conferences September 8 - 11

IMDX Reports Q2 2025 Results and Momentum Toward GraftAssureDx Launch

Aug 11, 2025, 4:05 PM EDT - 3 months ago

IMDX Reports Q2 2025 Results and Momentum Toward GraftAssureDx Launch

iMDx to Release Second Quarter 2025 Results on August 11, 2025 and Attend Needham Virtual MedTech and Diagnostics Conference

Aug 4, 2025, 4:05 PM EDT - 3 months ago

iMDx to Release Second Quarter 2025 Results on August 11, 2025 and Attend Needham Virtual MedTech and Diagnostics Conference

IMDX World Transplant Congress Late-Breaking Data Potentially Sets New Bar for Predicting Graft Rejection in Kidney Transplant Patients

Jul 30, 2025, 4:05 PM EDT - 3 months ago

IMDX World Transplant Congress Late-Breaking Data Potentially Sets New Bar for Predicting Graft Rejection in Kidney Transplant Patients

iMDx to Host Virtual KOL Event to Discuss its In-House dd-cfDNA Testing for Kidney Transplant Patients on August 15, 2025

Jul 28, 2025, 4:05 PM EDT - 3 months ago

iMDx to Host Virtual KOL Event to Discuss its In-House dd-cfDNA Testing for Kidney Transplant Patients on August 15, 2025

iMDx Reports Strong Head-to-Head Data in Kidney Transplant Rejection Testing

Jun 23, 2025, 4:05 PM EDT - 5 months ago

iMDx Reports Strong Head-to-Head Data in Kidney Transplant Rejection Testing

Oncocyte Changes Name to Insight Molecular Diagnostics Inc. (iMDx), Moves Headquarters to Nashville

Jun 17, 2025, 7:00 AM EDT - 5 months ago

Oncocyte Changes Name to Insight Molecular Diagnostics Inc. (iMDx), Moves Headquarters to Nashville

Medicare Boosts Reimbursement for Oncocyte's Flagship Technology

May 19, 2025, 4:05 PM EDT - 6 months ago

Medicare Boosts Reimbursement for Oncocyte's Flagship Technology

OncoCyte Corporation (OCX) Q1 2025 Earnings Call Transcript

May 12, 2025, 11:32 PM EDT - 6 months ago

OncoCyte Corporation (OCX) Q1 2025 Earnings Call Transcript

Oncocyte Reports Q1 2025 Results and Business Progress

May 12, 2025, 4:05 PM EDT - 6 months ago

Oncocyte Reports Q1 2025 Results and Business Progress

Oncocyte to Release First Quarter 2025 Results on May 12, 2025

May 7, 2025, 4:10 PM EDT - 6 months ago

Oncocyte to Release First Quarter 2025 Results on May 12, 2025

Oncocyte Provides Positive Update on Clinical Trial Progress

Apr 30, 2025, 8:30 AM EDT - 7 months ago

Oncocyte Provides Positive Update on Clinical Trial Progress

Oncocyte's Proprietary Assay Demonstrates Long-Term Clinical Validity

Apr 29, 2025, 8:30 AM EDT - 7 months ago

Oncocyte's Proprietary Assay Demonstrates Long-Term Clinical Validity

OncoCyte Corporation (OCX) Q4 2024 Earnings Call Transcript

Mar 24, 2025, 6:53 PM EDT - 8 months ago

OncoCyte Corporation (OCX) Q4 2024 Earnings Call Transcript

Oncocyte to Release Fourth Quarter 2024 Results on March 24, 2025

Mar 18, 2025, 4:05 PM EDT - 8 months ago

Oncocyte to Release Fourth Quarter 2024 Results on March 24, 2025

Oncocyte to Participate in BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference

Feb 11, 2025, 8:30 AM EST - 9 months ago

Oncocyte to Participate in BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference

Oncocyte Appoints Dr. Paul Billings as Consulting Chief Medical Officer

Jan 8, 2025, 8:30 AM EST - 11 months ago

Oncocyte Appoints Dr. Paul Billings as Consulting Chief Medical Officer

Oncocyte Expands Market Opportunity for VitaGraft™ Kidney

Jan 6, 2025, 4:05 PM EST - 11 months ago

Oncocyte Expands Market Opportunity for VitaGraft™ Kidney

OncoCyte Corporation (OCX) Q3 2024 Earnings Call Transcript

Nov 12, 2024, 8:52 PM EST - 1 year ago

OncoCyte Corporation (OCX) Q3 2024 Earnings Call Transcript

Oncocyte To Announce Third Quarter 2024 Financial Results on Nov. 12

Nov 6, 2024, 4:45 PM EST - 1 year ago

Oncocyte To Announce Third Quarter 2024 Financial Results on Nov. 12

Oncocyte Announces Participation in the LD Micro Main Event XVII Conference in Los Angeles

Oct 16, 2024, 4:15 PM EDT - 1 year ago

Oncocyte Announces Participation in the LD Micro Main Event XVII Conference in Los Angeles

OncoCyte Corporation (OCX) Q2 2024 Earnings Call Transcript

Aug 10, 2024, 1:00 PM EDT - 1 year ago

OncoCyte Corporation (OCX) Q2 2024 Earnings Call Transcript

Oncocyte Bolsters Executive Team with Key CFO Appointment: PRISM MarketView Highlights Strategic Leadership Move

Jun 24, 2024, 12:41 PM EDT - 1 year ago

Oncocyte Bolsters Executive Team with Key CFO Appointment: PRISM MarketView Highlights Strategic Leadership Move

Favorable Oncocyte VitaGraft Kidney Study Results Published in the New England Journal of Medicine

May 30, 2024, 4:47 PM EDT - 1 year ago

Favorable Oncocyte VitaGraft Kidney Study Results Published in the New England Journal of Medicine

OncoCyte Corporation (OCX) Q1 2024 Earnings Call Transcript

May 15, 2024, 10:15 PM EDT - 1 year ago

OncoCyte Corporation (OCX) Q1 2024 Earnings Call Transcript

Oncocyte Reports First Quarter 2024 Financial Results

May 15, 2024, 4:05 PM EDT - 1 year ago

Oncocyte Reports First Quarter 2024 Financial Results

OncoCyte Corporation (OCX) Q4 2023 Earnings Call Transcript

Apr 12, 2024, 1:44 PM EDT - 1 year ago

OncoCyte Corporation (OCX) Q4 2023 Earnings Call Transcript

Oncocyte Reports Full Year 2023 Financial Results

Apr 12, 2024, 6:00 AM EDT - 1 year ago

Oncocyte Reports Full Year 2023 Financial Results

Oncocyte to Announce Fourth Quarter and Full Year 2024 Financial Results

Apr 9, 2024, 4:05 PM EDT - 1 year ago

Oncocyte to Announce Fourth Quarter and Full Year 2024 Financial Results

OncoCyte Corporation (OCX) Q3 2023 Earnings Call Transcript

Nov 9, 2023, 9:36 AM EST - 2 years ago

OncoCyte Corporation (OCX) Q3 2023 Earnings Call Transcript

OncoCyte Corporation (OCX) Q2 2023 Earnings Call Transcript

Aug 10, 2023, 12:06 PM EDT - 2 years ago

OncoCyte Corporation (OCX) Q2 2023 Earnings Call Transcript

VitaGraft Kidney Expands Utility in Recurrent Primary Disease Patients

Jul 25, 2023, 9:08 AM EDT - 2 years ago

VitaGraft Kidney Expands Utility in Recurrent Primary Disease Patients

Oncocyte Announces 1-For-20 Reverse Stock Split

Jul 24, 2023, 1:35 PM EDT - 2 years ago

Oncocyte Announces 1-For-20 Reverse Stock Split

Oncocyte Begins Manufacturing Transplant Blood Test

Jun 27, 2023, 8:30 AM EDT - 2 years ago

Oncocyte Begins Manufacturing Transplant Blood Test

Oncocyte Corporation to Present at the LD Micro Invitational XIII

Jun 1, 2023, 4:15 PM EDT - 2 years ago

Oncocyte Corporation to Present at the LD Micro Invitational XIII

Oncocyte Reports First Quarter 2023 Financial Results

May 11, 2023, 8:00 AM EDT - 2 years ago

Oncocyte Reports First Quarter 2023 Financial Results

Oncocyte To Announce First Quarter 2023 Financial Results

Apr 27, 2023, 4:59 PM EDT - 2 years ago

Oncocyte To Announce First Quarter 2023 Financial Results

Oncocyte Presents New Data at AACR

Apr 18, 2023, 8:45 AM EDT - 2 years ago

Oncocyte Presents New Data at AACR

Oncocyte Announces Reduction in Force

Apr 12, 2023, 4:15 PM EDT - 2 years ago

Oncocyte Announces Reduction in Force

Oncocyte Announces Publication of DetermaIO Results from AtezoTRIBE Study in Metastatic Colorectal Cancer

Apr 7, 2023, 8:24 AM EDT - 2 years ago

Oncocyte Announces Publication of DetermaIO Results from AtezoTRIBE Study in Metastatic Colorectal Cancer

OncoCyte Corporation (OCX) Q4 2022 Earnings Call Transcript

Apr 3, 2023, 11:40 AM EDT - 2 years ago

OncoCyte Corporation (OCX) Q4 2022 Earnings Call Transcript

Oncocyte Reports Preliminary Fourth Quarter and Full Year 2022 Financial Results and Plans to File Form 12b-25 to Extend Filing Date of Its Form 10-K

Mar 31, 2023, 5:00 PM EDT - 2 years ago

Oncocyte Reports Preliminary Fourth Quarter and Full Year 2022 Financial Results and Plans to File Form 12b-25 to Extend Filing Date of Its Form 10-K

DefenestrationAtPrague
DefenestrationAtPrague Nov. 13 at 4:31 AM
$IMDX I already own more than renaissance, buying 5k more shares tomorrow. If only they had options back… Price Target is a reflection of M&A
1 · Reply
afc2881
afc2881 Nov. 12 at 11:17 PM
$IMDX John here since 2018!
1 · Reply
crypto_vibe67
crypto_vibe67 Nov. 12 at 8:49 PM
$IMDX NXXT grind then jump classic markup rhythm 🧗
0 · Reply
cache1b
cache1b Nov. 12 at 8:43 PM
$IMDX still in
0 · Reply
ocxfan
ocxfan Nov. 12 at 8:27 PM
$IMDX
1 · Reply
Cynovarx_917
Cynovarx_917 Nov. 12 at 8:25 PM
$IMDX
0 · Reply
PulseFocus2587
PulseFocus2587 Nov. 12 at 8:03 PM
$IMDX NXXT bidders fearless, offers thin, door open
0 · Reply
jackedmund99
jackedmund99 Nov. 12 at 7:58 PM
$IMDX very interesting that institutions own close to 51% of the stock insiders own close to 42% of the stock institutional fund ownership owns 2% of the stock and everyone else owns the rest amazing. The stock is hasn’t even been discovered.
1 · Reply
jackedmund99
jackedmund99 Nov. 12 at 7:49 PM
$IMDX need him and Company yesterday raised the target on the stock to nine dollars from 4 1/2 but it’s next week when I have to raise it to the mid teens market cap for this company should be easily could be $500 million right now it’s not overpriced
1 · Reply
jackedmund99
jackedmund99 Nov. 12 at 7:20 PM
$IMDX technology is being validated market cap still at $200 million is peanuts stock can literally be worth twice as much when the first dollar is cashed and that’s where it should be. This is probably a half $1 billion company before they start to sell product technology works going after huge market. It’s just the beginningthe fact that the stock is not getting trashed and it’s in tight hands. The best is yet to come fuck the shorts
1 · Reply
JohnPDaly
JohnPDaly Nov. 12 at 6:50 PM
$IMDX Anyone left here from Pre reverse split days?
2 · Reply
NY2CHI
NY2CHI Nov. 12 at 6:00 PM
$IMDX what a beast
0 · Reply
SirSloth
SirSloth Nov. 12 at 4:12 AM
$IMDX 👀
2 · Reply
jackedmund99
jackedmund99 Nov. 11 at 5:39 PM
$IMDX looks like this thing is getting ready to break out good volume today too after the report 60,000 shares solid bid 5000 shares but at seven stock prices 710 it’s gonna run right up to eight
1 · Reply
RUNNINWILD
RUNNINWILD Nov. 11 at 3:25 PM
$IMDX always risks but tremendous payout opportunity
0 · Reply
JarvisFlow
JarvisFlow Nov. 11 at 10:59 AM
Needham has adjusted their stance on Insight Molecular ( $IMDX ), setting the rating to Buy with a target price of 4.25 → 9.
0 · Reply
Bogwood
Bogwood Nov. 11 at 6:14 AM
$IMDX Very confident tone from the team and 2Q26 reiteration for FDA approval. I love how they highlighted how easy it is to continue into other organs, as if kidney's already a done deal. It inspires confidence that they're not just "wait and seeing" and instead are firing on all cylinders. Finally the firm has a product that isn't smoke and mirrors. However, the upcoming financing is still a game of chicken. I'm of the opinion any dip should be bought, as they've do not seem worried at all about securing another round before launch
2 · Reply
Doozio
Doozio Nov. 11 at 2:28 AM
$IMDX 👁️ 👀 yo TTWO. HTF 🐒🍌🧠⏰♾️
0 · Reply
jackedmund99
jackedmund99 Nov. 10 at 10:21 PM
$IMDX great meeting the pie is getting bigger - very good call so far
0 · Reply
jackedmund99
jackedmund99 Nov. 10 at 9:42 PM
$IMDX $IMDX fake report out by shorts - today’s Q right now shows they’re operating at a 53% profit margin start - doing the math - shorts are gonna attack things here because of course the stock has doubled and they’re screwed but the marketplace $IMDX is going after is huge and it’s their first test- they are one of the up-and-coming new technologies that are gonna help this industry so the hell with the shorts we’re talking about a market cap of $175 million going after A $1 billion plus marketplace for their first product. The shorts are once again shortsighted- fuck them
1 · Reply
d_risk
d_risk Nov. 10 at 9:32 PM
$IMDX - Insight Molecular Diagnostics Inc. - 10Q - Updated Risk Factors IMDX flags new risks from potential FDA regulation of LDTs, possible delays and costs tied to IVD approvals, and heightened Medicare reimbursement uncertainty for GraftAssureCore, all of which could materially impact revenue and operations. #MolecularDiagnostics #RegulatoryRisk #IVDApprovals #MedicareReimbursement #FDARegulation 🟢 Added 🟠 Removed https://d-risk.ai/IMDX/10-Q/2025-11-10
1 · Reply
JohnPDaly
JohnPDaly Nov. 10 at 9:12 PM
$IMDX We believe that regulatory clearance will enable us to gain a foothold in the market, after which we expect to begin to dramatically scale our business quarter by quarter. We expect this progress will enable us to surpass our near-term financial objectives, generate sustained free cash flow, and head towards $100 million in annual high-margin revenue growing at a double-digit pace.
1 · Reply